The aims of this study are to refine the phenotype inference of NAT2 genotyping and the identification of clinically relevant associations of the new genotype categories with cancer risk, differential treatment response or clinical outcome are beyond the aims of the study. This evidence concerns the gene NAT2 and cancer.